Wednesday, July 17, 2013

Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding

BI and EFSD commit €2.5 million to help accelerate European initiatives in key areas of diabetes research

INGELHEIM, Germany - Wednesday, July 17th 2013 [ME NewsWire]

(BUSINESS WIRE) For Non-US and Non-UK Media

The Boehringer Ingelheim (BI) and European Foundation for the Study of Diabetes (EFSD) partnership today announced the recipients of their European-wide funding initiative targeted at diabetes research. Totalling €2.5 million, these are the first grants to be awarded as part of the EFSD/Boehringer Ingelheim European Diabetes Research Programmes, which aim to stimulate and accelerate European research in diabetes.

The awards are given for outstanding research into cutting-edge approaches to diabetes, focusing on two areas of interest:

    Regulations of secretion and/or function of non-insulin peptides from the endocrine pancreas (basic research)
    Mechanisms relating renal dysfunction to cardiovascular disease in Type 2 Diabetes (clinical research)

In announcing the recipients, Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim, commented “These grants reflect our continued commitment to supporting medical innovation in diabetes research, a disease which affects over 370 million people worldwide. It is through continued independent research in this area that we will better understand how we can improve outcomes for patients with diabetes.”

The successful proposals were subject to a scientific review by a specialist independent committee, from which 3 winners were selected from across Europe, based on criteria including significance, approach and innovation.

The following proposals have been awarded funding:

    Stefan Amisten: King's College London - UK Identification and functional characterisation of peptide ligands of G-protein coupled receptors in mouse and human islets

    Hiddo Heerspink: University Medical Center Groningen - The Netherlands Urinary proteomics to predict and unravel mechanisms of renal and cardiovascular disease in diabetic nephropathy

    Markus van der Giet: Charity University Berlin - Germany Biomarker-based formula to predict HDL functionality in patients with chronic kidney disease and diabetes mellitus

Professor Andrew J. M. Boulton, President of EASD/EFSD, said “EFSD is proud to join forces with Boehringer Ingelheim to further explore one of the defining health problems of the 21st century. Diabetes remains insufficiently understood and its impact on those living with the condition is immeasurable. The quality of grant applications received is an encouraging sign of the continued efforts being made by researchers who have valuable contributions to make towards expanding our knowledge and understanding of this disease.”

Diabetes is a chronic condition which affects approximately 371 million people worldwide.1 Over the next 20 years, the number of people with the condition is expected to increase by 50%, reaching close to 552 million.2 Through innovative research, the EFSD/Boehringer Ingelheim European Diabetes Research Programmes aim to advance the knowledge of diabetes, its prevention and treatment with a view to easing the burden on people with diabetes.

A list of all recipients can be found on:

Please click on the link below for ‘Notes to Editors’ and ‘References’:


Dr. Ralph Warsinsky

Boehringer Ingelheim

Corporate Communications

55216 Ingelheim/Germany

Phone: +49 6132 77 7051



No comments:

Post a Comment